Search for 'Provider:Oncology and therapy,'

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

By Sánchez Torres, José Miguel. Clinical & Translational Oncology. 2013 . 15(6):477-83. , Formato Vancouver: Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I et al. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol. 2013 Jun;15(6):477-83.

Place Hold on Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

By Manso Sánchez, Luis. Annals of oncology: official journal of the European Society for Medical Oncology, 2013 . 24(1):109-16. , Formato Vancouver: Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013 Jan;24(1):109-16.

Place Hold on Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.

By Mendiola Fernández, César. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2013 . 31(20):2593-9. , Formato Vancouver: Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593–259.

Place Hold on Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

By Ciruelos Gil, Eva María. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2013 . 31(20):2586-92. , Formato Vancouver: Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013 Jul 10;31(20):2586-92.

Place Hold on Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.

Late Side Effects in Men With Intermediate- and High-RiskProstate Cancer Treated With High-Dose Radiation Therapy andAndrogen Deprivation (DART 01/05): Secondary Endpoints Froma Phase 3 Clinical Trial.

By Cabeza Rodríguez, Mª Ángeles. International Journal of Radiation Oncology Biology Physics, 2013 . 87(2):S105. , Formato Vancouver: Zapatero A, Guerrero A, Maldonado X, Álvarez A, San Segundo CG, Cabeza M, et al. Late side effects in men with intermediate- and high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation (DART 01/05): Secondary endpoints from a phase 3 clinical trial. Int J Radiat Oncol Biol Phys. 2013;87(2):S105 [Annual Meeting of the American Society for Radiation Oncology (55. 2013. Atlanta, GA.)]

Place Hold on Late Side Effects in Men With Intermediate- and High-RiskProstate Cancer Treated With High-Dose Radiation Therapy andAndrogen Deprivation (DART 01/05): Secondary Endpoints Froma Phase 3 Clinical Trial.

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.

By Cortés-Funes Castro, Hernán. Oncology, 2012 . 82(4):218-27. , Formato Vancouver: Thomssen C, Pierga JY, Pritchard KI, Biganzoli L, Cortés-Funes H, Petráková K, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology. 2012;82(4):218-27.

Place Hold on First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.

Long-term Changes in Pulmonary Function After Incidental Lung Irradiation for Breast Cancer: A Prospective Study With 7-Year Follow-up.

By Pérez-Regadera Gómez, José Fermín. International Journal of Radiation Oncology*Biology*Physics, 2012 . 84(5):e565-70. , Formato Vancouver: Jaén J, Vázquez G, Alonso E, De Las Peñas MD, Díaz L, De Las Heras M, et al. Long-term changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study with 7-year follow-up. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e565-70.

Place Hold on Long-term Changes in Pulmonary Function After Incidental Lung Irradiation for Breast Cancer: A Prospective Study With 7-Year Follow-up.

Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy.

By Ruiz Alonso, Ana. Clinical and Translational Oncology, 2012 . 14(10):740-6. , Formato Vancouver: Mañas A, Cerezo L, de la Torre A, García M, Alburquerque H, Ludeña B, et al. Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy. Clin Transl Oncol. 2012 Oct;14(10):740-6.

Place Hold on Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy.

Consensus of the Spanish Society of Radiation Oncology (SEOR) Brachytherapy Group on brachytherapy in Breast Cancer.

By Díaz Fuentes, Raúl | Murillo González, María Teresa. Clinical and Translational Oncology, 2012 . 14(3):177-82. , Formato Vancouver: Samper-Ots PM, Murillo MT, Díaz-Fuentes R, Guinot JL, et al. Consensus of the Spanish Society of Radiation Oncology (SEOR) Brachytherapy Group on Brachytherapy in breast cancer. Clin Transl Oncol. 2012 Mar;14(3):177-82.

Place Hold on Consensus of the Spanish Society of Radiation Oncology (SEOR) Brachytherapy Group on brachytherapy in Breast Cancer.

Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.

By Pérez-Regadera Gómez, José Fermín. Clinical and Translational Oncology, 2012 . 14(5):362-8. , Formato Vancouver: Rodríguez Pérez A, Samper Ots PM, López Carrizosa MC, Pérez-Regadera Gómez JF, Zapatero Ortuño J, Sáez Garrido Jde D, et al. Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed. Clin Transl Oncol. 2012 May;14(5):362-8.

Place Hold on Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

By Castellano, Daniel. Annals of Oncology, 2011 . 22(12):2646-2653. , Formato Vancouver: Bellmunt J, González Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646-53.

Place Hold on Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

By Castellano, Daniel. Clinical and Translational Oncology, 2011 . 13(12):869-877. , Formato Vancouver: Calvo Aller E, Maroto P, Kreif N, González Larriba JL, López-Brea M, Castellano D, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011;13(12):869-77.

Place Hold on Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

By Cortés-Funes Castro, Hernán. Annals of Oncology, 2011 . 22(3):595-602. , Formato Vancouver: Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22(3):595-602.

Place Hold on First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

Update on the diagnosis of cancer of unknown primary (CUP) origin

By Hitt Sabag, Ricardo | Homet, Blanca. Clinical and Translational Oncology, 2011 . 13(7):434-441. , Formato Vancouver: Ariza A, Balañá C, Concha Á, Hitt R, Homet B, Matilla A, Alba E. Update on the diagnosis of cancer of unknown primary (CUP) origin. Clin Transl Oncol. 2011Jul;13(7):434-41.

Place Hold on Update on the diagnosis of cancer of unknown primary (CUP) origin

PITASOR epidemiological study: prevalence, incidence and treatment of anaemia in radiation therapy oncology departments in Spain

By Pérez Escutia, Mª Ángeles. Clinical and Translational Oncology, 2011 . 13(5):322-327. , Formato Vancouver: Samper Ots PM, Muñoz J, Biete A, Ortiz MJ, Acuña M, Cabrera J, et al. PITASOR epidemiological study: prevalence, incidence and treatment of anaemia in radiation therapy oncology departments in Spain. Clin Transl Oncol. 2011;13(5):322-7.

Place Hold on PITASOR epidemiological study: prevalence, incidence and treatment of anaemia in radiation therapy oncology departments in Spain

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

By Grávalos Castro, Cristina. Critical Reviews in Oncology/Hematology, 2011 . 77(1):78-84. , Formato Vancouver: Sastre J, Aranda E, Grávalos C, Massutí B, Varella García M, Rivera F, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011;77(1):78-84.

Place Hold on First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

By Cortés-Funes Castro, Hernán | Gómez Martín, Carlos | Grávalos Castro, Cristina. Clinical and Translational Oncology, 2011 . 13(3):179-184. , Formato Vancouver: Grávalos C, Gómez Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011;13(3):179-84.

Place Hold on Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

By Hitt Sabag, Ricardo. Annals of Oncology, 2011 . 22(5):1078-1087. , Formato Vancouver: Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078-87.

Place Hold on Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

By Ciruelos Gil, Eva María. The Lancet. Oncology, 2014 . 15(11):1269-78. , Formato Vancouver: Von Minckwitz G, Puglisi F, Cortés J, Vrdoljak E, Marschner N, Zielinski C et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78.

Place Hold on Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

By Manso Sánchez, Luis. The Lancet. Oncology, 2014 . 15(4):406-14. , Formato Vancouver: Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014 Apr;15(4):406-14.

Place Hold on Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

By Lahuerta Palacios, Juan José . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014 . 32(20):2173-80. , Formato Vancouver: Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014 Jul 10;32(20):2173-80.

Place Hold on Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

By Lahuerta Palacios, Juan José . The Lancet. Oncology, 2014 . 15(12):e538-48. , Formato Vancouver: Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48.

Place Hold on International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

By Castellano, Daniel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014 . 32(2):76-82. , Formato Vancouver: Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014 Jan 10;32(2):76-82.

Place Hold on Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

By Grande García, Carlos. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014 . 32(15):1595-604. , Formato Vancouver: Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González Campos J et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014 May 20;32(15):1595-604.

Place Hold on Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

By Ciruelos Gil, Eva María. The Lancet. Oncology, 2015 . 16(16):1700-10. , Formato Vancouver: Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015 Dec;16(16):1700-10.

Place Hold on Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

By Sánchez Torres, José Miguel. JAMA oncology, 2015 . 1(2):149-57. , Formato Vancouver: Karachaliou N, Mayo de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F et al; Spanish Lung Cancer Group. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol. 2015 May;1(2):149-57.

Place Hold on Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

By Ciruelos Gil, Eva María. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 . 33(14):1564-73. , Formato Vancouver: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R et al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2015 May 10;33(14):1564-73.

Place Hold on CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

By Manso Sánchez, Luis | Ciruelos Gil, Eva María. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(2):160-6. , Formato Vancouver: Salvador J, Manso L, De la Haba J, Jaén A, Ciruelos E, De Villena MC et al. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol. 2015 Feb;17(2):160-6.

Place Hold on Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

By Cabeza Rodríguez, Mª Ángeles. The Lancet. Oncology, 2015 . 16(6):e262. , Formato Vancouver: Zapatero A, Guerrero A, Maldonado X, Alvárez A, González San Segundo C, Cabeza Rodríguez MA et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Mar;16(3):320-7.

Place Hold on High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

By Paz-Ares Rodríguez, Luis. The Lancet. Oncology, 2015 . 16(3):328-37. , Formato Vancouver: Paz Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37.

Place Hold on Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study.

By Cruz Bértolo, Javier de la. Urologic oncology, 2015 . 33(1):19.e7-19.e15. , Formato Vancouver: Schmidt S, Francés A, Lorente Garín JA, Juanpere N, Lloreta Trull J, Bonfill X et al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015 Jan;33(1):19.e7-19.e15.

Place Hold on Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

By Agulló Ortuño, María Teresa | Díaz García, C. Vanesa | Agudo López, Alba | Pérez, Carlos | Cortijo, Ana | Paz-Ares Rodríguez, Luis | Pozo Rodríguez, Francisco | Cortés-Funes Castro, Hernán | López Martín, José Antonio. Journal of cancer research and clinical oncology, 2015 . 141(1):43-53. , Formato Vancouver: Agulló Ortuño MT, Díaz García CV, Agudo López A, Pérez C, Cortijo A, Paz Ares L et al. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53.

Place Hold on Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

By Grávalos Castro, Cristina. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . ;26(3):535-41. , Formato Vancouver: Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015 Mar;26(3):535-41.

Place Hold on Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

By Lahuerta Palacios, Juan José . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015 . 33(6):657-64. , Formato Vancouver: Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015 Feb 20;33(6):657-64.

Place Hold on Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

SEOM clinical guidelines in early-stage breast cancer 2015.

By Ciruelos Gil, Eva María. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):939-45. , Formato Vancouver: García Sáenz JA, Bermejo B, Estevez LG, Palomo AG, González Farre X, Margeli M et al. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):939-45.

Place Hold on SEOM clinical guidelines in early-stage breast cancer 2015.

SEOM guidelines for the management of Malignant Melanoma 2015.

By Martín, J.A.L.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):1030-5. , Formato Vancouver: Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba J et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015 Dec;17(12):1030-5.

Place Hold on SEOM guidelines for the management of Malignant Melanoma 2015.

Seom guidelines for the treatment of gastric cancer 2015.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):996-1004. , Formato Vancouver: Martin Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P et al. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):996-1004.

Place Hold on Seom guidelines for the treatment of gastric cancer 2015.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

By Grávalos Castro, Cristina. Targeted oncology, 2016 . 11(3):383-400. , Formato Vancouver: Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400.

Place Hold on Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Anticancer mechanisms of cannabinoids.

By Sánchez, C. Current oncology (Toronto, Ont.), 2016 . 23(2):S23-32. , Formato Vancouver: Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Curr Oncol. 2016 Mar;23(2):S23-32.

Place Hold on Anticancer mechanisms of cannabinoids.

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

By Rodríguez Garzotto, Analía | Díaz García, C. Vanesa | Agudo López, Alba | Prieto García, Elena | Ponce Aix, Santiago | López Martín, José Antonio | Paz-Ares Rodríguez, Luis | Iglesias Docampo, Lara | Agulló Ortuño, María Teresa. Medical oncology (Northwood, London, England), 2016 . 33(10):105. , Formato Vancouver: Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.

Place Hold on Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma.

By Parra Pont, Luis | Pedraza Abad, José María | Palazón Cabanes, Javier | Robustillo Rego, Manuel | Grandes Elías, Daniel | Martín Díaz, Marcos | Lagarón Comba, Emilio José | Garrido Ruiz, María Concepción. Oncology and therapy, 2016 . 4(1):129-34. , Forma: Parra L, Martín M, Garrido M, Pedraza JM, Palazón J, Robustillo M et al.Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma. Oncol Ther. 2016;4(1):129-34.

Place Hold on Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

By Paz-Ares Rodríguez, Luis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2016 . 27(3):423-9. , Formato Vancouver: Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9.

Place Hold on Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.